Price History

Hover for the daily close. The dotted line marks the period open.

Compare QTTB with… →

QTTB Key Statistics

As of Sep 4, 2026

Trading

Open: $12.60
Previous Close: $12.80
Day's Range: 11.50–12.70
52-Week Range: 1.68–23.57
Volume: 851.50K
Beta: −0.38

Valuation

Market Cap: $356.94M
P/E Ratio: 3.82
P/S ratio: 6.64
EPS (ttm): 3.14

Financials (FY)

Revenue (FY): $53.74M
Net Income (FY): $29.82M
Profit margin: 62.87%
Shares Outstanding: 29.77M
1-Year Return: +622.29%

Dividend and dates

Avg Volume: 1.14M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

QTTB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−68.57%+261.14%

2018*20192020202120222023202420252026*

Year	Return
2026 (partial year)	+261.14%
2025	−3.49%
2024	−68.57%
2023	−51.75%
2022	−65.38%
2021	−67.76%
2020	−45.46%
2019	−7.42%
2018 (partial year)	+19.83%

As of September 4, 2026.

QTTB Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$53.74M	$29.82M	55.5%
2024	$0.00	−$47.73M	—
2023	−$6.65M	−$53.74M	808.0%
2022	$6.65M	−$42.81M	−643.6%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$53.74M	—	$16.90M	$29.82M	55.5%
2024	$0.00	—	−$66.10M	−$47.73M	—
2023	−$6.65M	—	−$48.26M	−$53.74M	808.0%
2022	$6.65M	—	−$39.23M	−$42.81M	−643.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

QTTB Valuation vs Biotechnology Median

Median of 656 stocks

Metric	QTTB	Biotechnology median	vs median
P/E	3.82	12.57	0.3x the median
P/S ratio	6.64	15.26	56% below
Profit margin	62.87%	0.00%	62.9 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Q32 Bio Inc. (QTTB) carries a market capitalisation of $356.94M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 22.

Over the past 52 weeks the price has ranged from $1.68 to $23.57. QTTB last closed at $11.99 on September 4, 2026. That is −$0.81 (−6.33%) against the previous close. The latest close sits 613.69% above that 52-week low.

Financial Health

In fiscal 2025, Q32 Bio Inc. reported revenue of $53.74M. The same year closed with net income of $29.82M. The reported profit margin is 62.87%. That is 62.9 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 3.14.

Across the 4 fiscal years on file, revenue moves from $6.65M in 2022 to $53.74M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 3.82. That is 0.3 times the Biotechnology median of 12.57. The price-to-sales ratio is 6.64. On price-to-sales that is 56.48% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at −0.38. Daily returns over the trailing 8 years annualize to a volatility of 111.93%. The trailing one-year price return is +622.29%. Measured over 5 years, that is −38.32% a year compounded.

Growth & Income

No dividend is on file for QTTB.

So far in 2026 the price is +261.14%. Across the complete calendar years on file, 2025 returned −3.49% and 2024 returned −68.57%. Of the 7 complete calendar years on file, 0 finished higher.

Peer Comparison

Q32 Bio Inc. (QTTB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Q32 Bio Inc.	QTTB	$356.94M	3.8
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Q32 Bio Inc. trades at a P/E of 3.8.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Q32 Bio Inc.

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.

Visit website →

Q32 Bio Inc. (QTTB) Stock Analysis